X

Trial Profile

Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable high grade gliomas patients

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 06 May 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olaparib (Primary) ; Temozolomide
Indications Glioblastoma; Glioma
Focus Adverse reactions; Therapeutic Use
Acronyms OLA-TMZ-RTE-01

Most Recent Events

26 Apr 2024 Planned End Date changed from 4 Oct 2024 to 4 Mar 2025.
26 Apr 2024 Planned primary completion date changed from 4 Apr 2024 to 13 Sep 2024.
06 Jun 2023 Results (n=30) of phase 1 step assessing safety and efficacy of olaparib combined with radiotherapy plus temozolomide in high grade glioma patients, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com